Topics

Morphosys shares fall after dermatitis treatment flops

00:51 EDT 29 Oct 2019 | Reuters

German biotech company Morphosys halted development of an experimental atopic dermatitis treatment that analysts had pinned hopes of blockbuster sales potential on, sending its shares down as much as 6.8% on Tuesday.

Original Article: Morphosys shares fall after dermatitis treatment flops

NEXT ARTICLE

More From BioPortfolio on "Morphosys shares fall after dermatitis treatment flops"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...